A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

NCT01474083 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: GK1-399 (formerly TTP399)
DRUG: GK1-399 (formerly TTP399)
DRUG: GK1-399 (formerly TTP399)
DRUG: Placebo

Sponsor

vTv Therapeutics